Doublecortin-expressing cell types in temporal lobe epilepsy

Joan Y. W. Liu1,2,7, Mar Matarin1, Cheryl Reeves1,2, Andrew W. McEvoy1,5, Anna Miserocchi5, Pamela Thompson1,4,6, Sanjay M. Sisodiya1,3,6 and Maria Thom1,2*

Abstract

Doublecortin (DCX) is widely regarded as a marker of immature and migrating neurons during development. While DCX expression persists in adults, particularly in the temporal lobe and neurogenic regions, it is unknown how seizures influence its expression. The aim of the present study was to explore the distribution and characteristics of DCX-expressing cells in surgical and postmortem samples from 40 adult and paediatric patients, with epilepsy and with or without hippocampal sclerosis (HS), compared to post mortem controls. The hippocampus (pes and body), parahippocampal gyrus, amygdala, temporal pole and temporal cortex were examined with DCX immunohistochemistry using four commercially-available DCX antibodies, labelled cells were quantified in different regions of interest as well as their co-expression with cell type specific markers (CD68, Iba1, GFAP, GFAPβ, nestin, SOX2, CD34, OLIG2, PDGFRβ, NeuN) and cell cycle marker (MCM2). Histological findings were compared with clinical data, as well as gene expression data obtained from the temporal cortex of 83 temporal lobe epilepsy cases with HS. DCX immunohistochemistry identified immature (Nestin−/NeuN−) neurons in layer II of the temporal neocortex in patients with and without epilepsy. Their number declined significantly with age but was not associated with the presence of hippocampal sclerosis, seizure semiology or memory dysfunction. DCX+ cells were prominent in the paralaminar nuclei and periamygdalar cortex and these declined with age but were not significantly associated with epilepsy history. DCX expressing cells with ramified processes were prominent in all regions, particularly in the hippocampal subgranular zone, where significantly increased numbers were observed in epilepsy samples compared to controls. DCX ramified cells co-expressed Iba1, CD68 and PDGFRβ, and less frequently MCM2, OLIG2 and SOX2, but no co-localization was observed with CD34, nestin or GFAP/GFAPβ. Gene expression data from neocortical samples in patients with TLE and HS supported ongoing DCX expression in adults. We conclude that DCX identifies a range of morphological cell types in temporal lobe epilepsy, including immature populations, glial and microglial cell types. Their clinical relevance and biological function requires further study but we show some evidence for alteration with age and in epilepsy.

Keywords: Doublecortin, Temporal lobe epilepsy, Hippocampus, Memory, Microglia

Introduction

Doublecortin (DCX) is a microtubule-associated protein critical for normal neuronal migration during development. It has been widely used as a reliable marker to study post-mitotic, immature neurons in the adult mammalian brain [11, 14, 33, 37] as well as responses of these cell types to brain insults [9, 25, 51]. There is anatomically restricted expression in the normal mature mammalian brain, with DCX+ multipolar and ‘tangled’ neurons reported in cortical layer II, mainly in the temporal lobe, in a variety of species [36, 49] and in the peri-amygdala association cortex and amygdala [52]. The physiological function of persisting DCX+ neurons is unknown: roles in olfactory processing and memory have been postulated [6]. DCX+ neurons remain relatively unexplored in humans and their clinical significance is uncertain. DCX+ populations diminish with age in animals [6] but studies have suggested seizure-enhanced maturation and proliferation of DCX+ cell types occurs in temporal lobe epilepsy (TLE) [9, 28, 40] indicative of their underlying plasticity...
and responsiveness. In addition, reports have noted DCX expression in non-neuronal cell types, including in relation to cortical pathology and brain injury and repair [25, 46].

The aim of this study was to further explore the morphology, phenotype, distribution and density of DCX + cells in TLE. We included surgical samples from a wide age range both with and without hippocampal sclerosis (HS), the commonest pathology in TLE [4]. We compared this to findings in post-mortem (PM) samples from patients with epilepsy and HS and non-epilepsy controls to explore any differences in the morphology and number of DCX + cells between these groups. In addition we compared the neuropathological findings to available gene-expression data from a parallel study of the temporal lobe cortex from a large series of TLE patients. Neuropathology findings were also correlated with clinical epilepsy history, including type of seizures, aura and any memory dysfunction, to explore pathophysiological roles of these cell types.

Methods
Case selection
Fifty-two cases were included in the histological study (Table 1). Adult temporal lobe epilepsy (TLE) cases from patients undergoing elective surgery for the treatment of refractory epilepsy (n = 19) were selected from the databases of the Epilepsy Society Brain and Tissue Bank at UCL, Institute of Neurology and pediatric TLE surgical cases (n = 5) were obtained from Great Ormond Street Hospital NHS Trust. Adult post mortem (PM) tissue from patients with (n = 16) or without (n = 12) epilepsy during life (healthy controls) was obtained from the Epilepsy Society and MRC sudden death brain banks respectively; none of these patients had undergone neurosurgical treatments during life. The study has ethical approval and all cases were consented for use in research (Ethics committee approval NRES17/SC/0573). In 18/24 surgical cases and 8/16 of the epilepsy PM cases, hippocampal sclerosis (HS) ILAE type 1 [5] was present. None of these cases had additional temporal lobe sclerosis/cortical dysplasia [43] or other lesion.

Tissue was examined from six regions of the temporal lobe in the majority of adult surgical cases, including: (i) temporal neocortex (superior temporal gyrus to fusiform gyrus at 1 cm rostral to temporal pole) (Fig. 1a), (ii) temporal pole, (iii) mid-hippocampus body, (iii) pes hippocampus, (iv) parahippocampal gyrus (PHG) and (v) amygdala. As a standard anterior temporal lobectomy procedure was performed and a routine tissue handling and processing protocol was followed, the regions selected were anatomically comparable between cases. In surgical cases, the amygdala tissue was typically fragmented which limited identification of all subnuclei. In PM cases, coronal sections of the mid hippocampal body, adjacent temporal cortex and/or sections through the entire mid to caudal amygdala, including the paralaminar nuclei, were examined (Fig. 2a, Additional file 1: Table S1 for details).

Immunohistochemistry
Immunohistochemistry for DCX was carried out on 5 μm thick formalin-fixed, paraffin-embedded sections. We trialed four DCX commercially-available antibodies on selected

| Table 1 | Clinical and pathology details of cases and control groups (Further detail of each case is available in Additional file 1: Table S1). |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Group   | Tissue type | NUMBER | Predominant pattern of HS in body | Age (at surgery or death); mean (range, years) | Gender | Regions examined/study |
|---------|-------------|--------|-----------------------------------|-----------------------------------------------|--------|-----------------------|
| Adult epilepsy TLE/HS (S1–13) | Surgical Fixed | 13 | ILAE Type 1 HS | 41.3 (22–54) | 7F: 6 M | HB, PES, PHG, T Pole, TLobe, Amyg / q IHC |
| Paediatric epilepsy TLE/HS (S1–5) | Surgical Fixed | 5 | ILAE type 1 HS only | 12.2 (8–15) | 2F: 3 M | HB, TLobe / q IHC |
| Adult epilepsy TLE/NO HS (S19–24) | Surgical Fixed | 6 | NO HS | 28.6 (24–35) | 2F: 4 M | HB, PES, PHG, T Pole, TLobe, Amyg / q IHC |
| Adult epilepsy (EPM1–16) | Post Mortem | 16 | ILAE type 1 HS in 8 CASES | 48.7 (18–75) | 8F: 8 M | HB, PHG, Amyg, Temporal Cortex (Both hemispheres included in 4 cases) / q IHC |
| Adult non-epilepsy controls (C1–12) | Post mortem | 12 | No HS | 56.4 (28–85) | 5F: 7 M | HB, PHG, Amyg, Temporal Cortex / q IHC |
| Adult epilepsy TLE/HS | Fresh | 83 77° | All HS (16 with TLS) All HS (15 with TLS) | 36.3 (16–63) 35.6 (16–57) | 45F: 38M 39F: 38M | Middle temporal gyrus (cortex) / RNA |
| Adult non-epilepsy controls | Fresh | 73° | No HS | 50.8 (20–79) | 14F: 53F 30F: 29M | Middle temporal gyrus (cortex) / RNA |

°Surgical epilepsy case, EPM adult epilepsy post-mortem, C Post-mortem control, HB Hippocampal body, PES pes hippocampus, PHG parahippocampal gyrus, T Pole temporal pole, TLobe temporal lobe, TLE temporal lobe epilepsy, Amyg amygdala, HS hippocampal sclerosis, qIHC qualitative and quantitative immunohistochemistry, RNAseq RNA sequencing and expression analysis, ILAE International League against epilepsy, TLE temporal lobe epilepsy.

°Only samples from adolescence and young and middle adulthood period. Controls from Kang et al.
°Samples obtained from the MRC brain bank, Edinburgh. A1C = Primary auditory cortex
surgical and PM cases. All four antibodies were previously validated in publications on human tissues [9, 28, 34, 40, 46] (Table 2; DCX Ab1 to 4). All DCX antibodies showed immunopositive labelling, but DCX Ab1 (clone 4604, Cell signaling, Boston, USA) labelled a greater diversity of cell types, and more intense labelling was observed in both surgical and PM human brain tissues. Consequently, DCX Ab1 was used across all cases for the descriptive and quantitative analysis. Double label immunofluorescent studies were performed on all anatomical regions of five selected surgical cases (Additional file 1: Table S1); combinations included DCX Ab1 with different DCX antibodies, and DCX Ab1 with astroglial (GFAP, GFAP-β), microglial (Iba1, HLA-DR, CD68), mature neuronal (NeuN), immature/stem cells...
(nestin, CD34, SOX2), oligodendroglia (OLIG2), NG2-cells and pericytes (PDGFRβ) [11, 16] and cell cycle markers (MCM2). Details of the immunostaining protocols are included in Table 2 and the Additional file 2.

Quantitative and qualitative analysis
DCX-immuno-labelled cells (DCX+) at the boundaries of cortical layer I/II in the temporal lobe of all cases were quantified using Image pro plus (Media Cybernetics, Cambridge, UK). Sequential images were captured at ×40 using a Leica DBMR microscope along the entire length of layer 1 and II from the gyrus to the sulcus of the most inferior-mesial gyrus (fusiform gyrus (FG) or inferior temporal gyrus (ITG))(Fig. 1a). DCX+ cells of different morphologies were counted and expressed as cells per mm of gyrus length. DCX+ cell types in other anatomical regions were semi-quantified as: (0) absent, (+) rare/occasional, (++) moderate numbers, (+++) many cells. In PM cases where the entire coronal cross-section of the paralaminar nucleus was present, the presence of DCX+ cells was evaluated as: (0) absent, (+) single cluster, (++) 2–3 clusters, and (+++) > 4 clusters. In the adjacent peri-amygdala cortex (PAC; Fig. 2a) DCX in the superficial cortex was assessed as: (+) occasional single DCX+ cell, (++) several single cells or one cluster, (+++) 2–3 clusters, (++++) > 4 clusters. Qualitative examinations of double-labelled sections were carried out with a Zeiss Axio Imager Z2, and confocal laser scanning microscope (LSM-Meta 710, Zeiss, Göttingen, Germany). The software, Zen 2012 blue lite version (Zeiss, Göttingen, Germany), was used to view z-stacks of confocal images, and to compose three-dimensional orthogonal projections.

DCX mRNA analysis
Histology data was compared to DCX mRNA expression analyses from 83 surgical TLE cases (Table 1); in 16 of these cases there was evidence of temporal neocortical sclerosis (layer II/III neuronal loss and gliosis) in addition to hippocampal sclerosis [43]. TLE samples were obtained from the UCL Epilepsy Society Brain and tissue bank and compared to 73 PM non-epilepsy control tissues samples from the MRC Sudden Death Brain and Tissue Bank (Table 1). This data formed part of a separate study (Matarin et al., in preparation). We also compared this data to pre-existing expression array data; specifically DCX mRNA expression in ten different brain regions of non-epilepsy control cases including occipital, temporal, frontal, hippocampus, putamen, thalamus, substantia nigra, white matter, medulla and cerebellum as well as different life periods from embryonic to late adulthood [21].

For temporal lobe cases (patients and controls), RNA was isolated from the middle temporal gyrus (MTG) cortex and samples were randomly placed and hybridized to Affymetrix Exon 1.0 ST arrays as previously described [22]. Control tissue from other brain regions and different
life periods were also originally analysed with Affymetrix Exon 1.0 ST arrays [21] and data files were downloaded from the NCBI Gene Expression Omnibus (accession GSE25219 and GSE46706). Quality control analyses included background correction, quantile normalization, log2 transformation and median polishing probe-set summarization. The effects of several methodological and biological covariates were tested for significance and was included in the linear regression or MANOVA models when significant. All gene expression data was analyzed with Affymetrix Power Tools software package and Partek Genomics Suite (Partek Incorporated, St. Louis, MO, USA) and R software.

Clinical data
The age of onset of seizures, age at surgery, seizure types, laterality and outcomes at two years following surgery were obtained from the clinical records of epilepsy patients (Table 1 and Additional file 1: Table S1). Pre-operative memory function tests were carried out as part of the routine clinical assessment as previously described [44] and detailed in Additional file 2: Methods. Data on memory function was available in 15 adult surgical patients (Additional file 1: Table S1). Statistical analysis was carried out between pathology and clinical groups using non-parametric tests (including Kruskal-Wallis with post-hoc corrections and Spearman correlation) SPSS (IBM, California, version 22); p values of ≤0.05 were regarded as significant.

Results
Qualitative findings
DCX+ neuronal cell types
Neuronal-appearing unipolar (Fig. 1b), bipolar (Fig. 1c) and multipolar DCX+ cells (Fig. 1d) were identified mainly at the interface between layer I and II of the temporal cortex as single cells or more rarely in clusters or rows (Fig. 1d); they were observed in 18 of the 22 surgical cases studied and henceforth are collectively referred to as ‘layer II DCX+ cells’. The processes of multipolar tufted cells extended mainly perpendicularly to the cortical surface, projecting into layer I, where rarer horizontally-orientated DCX+ cells and processes could be observed. In all cases, layer II DCX+ cells intermingled with other

Table 2 Immunohistochemistry panel

| Antibody | Product code, Supplier | Dilution (method) | Target Epitope |
|----------|------------------------|-------------------|----------------|
| DCX      | Ab1                     | 4606, Cell Signaling Tech. Boston, US. *Used in [28] | 1:250 (IHC, IF) Amino acid sequence 40–70 and 350–410 of human DCX |
|          | Ab2                     | AB18723, Abcam, Cambridge, UK. *Used in [34, 40] | 1:4000 (IF) AA 300 to the C-terminus of synthetic human DCX |
| DCX      | Ab3                     | SC-8066, Santa Cruz Biotech. Heidelberg, Germany. *Used in [11, 24, 27] | 1:400 (IF) C-terminal 365–402 of human DCX |
| DCX      | Ab4                     | AB2253, EMD Millipore, Watford UK. *Used in [45, 46] | 1:1000 (IHC, IF) C-terminus 350–365 |
| Nestin   | Ab2                     | AB22035, Abcam, Cambridge, UK. | 1:1000 (IHC, IF) 150 aa recombinant fragment from human nestin conjugated to GST |
| Nestin   | Ab1                     | AB105389, Abcam, Cambridge, UK. | 1:100 (IF) Synthetic peptide corresponding to the C terminus of Human Nestin. |
| Sox 2    | Ab2                     | AB5603, EMD Millipore, Herfordshire, UK. | 1:400 (IF) KLH-conjugated linear peptide corresponding to a C-terminal region sequence of human Sox2 |
| GFAP-δ   | Ab2                     | AB93251, Abcam, Cambridge, UK. | 1:4000 (IF) Synthetic peptide conjugated to KLH derived from within residues 350 to the C-terminus of Mouse GFAP δ |
| GFAP     | Ab1                     | Z0334, DAKO, Cambridgeshire, UK. | 1:1500 (IF) GFAP |
| NeuN     | Ab2                     | MAB377, EMD Millipore, Herfordshire, UK. | 1:100 (IF) Purified neuronal nuclei |
| Iba1     | Ab2                     | 019–19,741, WAKO, Osaka, Japan. | 1:6000 (IF) Synthetic peptide corresponding to C-terminus of Iba1 |
| CD68     | Ab2                     | AB783, Abcam, Cambridge, UK. | 1:50 (IF) Macrophages, microglia |
| CD34     | Ab2                     | IR632, DAKO, Cambridgeshire, UK. | 1:25 (IF) Endothelial cells |
| Olig 2   | Ab2                     | AB9610, EMD Millipore Hertfordshire, UK | 1:200 (IF) Recombinant mouse Olig-2 |
| PDGFR-beta | Ab2                  | AB32570, Abcam, Cambridge, UK. | 1:1000 (IF) Synthetic peptide within Human PDGF Receptor beta aa 1050 to the C-terminus |
| MCM2     | Ab2                     | 610,700, BD biosciences, Oxford, UK. | 1:900 (IF) Human BM28 aa. 725–888 |

For all antibodies, sections were pre-treated in sodium citrate solution (pH 6.0) microwaved at 800 W for twelve minutes. All primary antibodies were incubated overnight at 4 °C, except for anti-Iba1, CD68 and GFAP which were incubated for an hour at room temperature, and anti-GFAP δ which was incubated for 48 h at 4 °C. *Previous studies using DCX in human tissue studies. Abbreviations: IHC immunohistochemistry, IF immunofluorescence.
DCX+ cells were also observed in the temporal pole of FG compared to MTG in surgical TLE cases. Layer II zone (Fig. 1j). Occasional cells were also noted alongside neurons in the developing fetal brain in the periventricular (Fig. 2b-d). These DCX + cells were sometimes arranged layer II (Fig. 1b) and occasionally with larger DCX + cells noted, particularly along the ventricle wall in the caudal gates in the paralaminar nucleus of the amygdala was presented. All DCX antibodies labelled clusters of small DCX+ cells, mainly in the superficial cortex of the PAC (Fig. 1e). Ramified DCX+ cells were present in all regions of all TLE cases, with and without HS, and all PM cases and noted in the gray and white matter. In the hippocampus, ramifications of DCX+ cells were particularly prominent in the hilus and subgranular zone of the dentate gyrus, extending through the granule cell layer. Occasional clusters or columns of DCX+ cells were seen (Fig. 1g) and proximity to CA1 pyramidal neurones. There were also present in the pes hippocampus and PHG in all cortical layers and white matter. Ramified cells were morphologically reminiscent of microglia and NG2+ cells as well as immature migrating neurons in the developing fetal brain in the periventricular zone (Fig. 1i). Occasional cells were also noted alongside vessels. In addition, a population of small round DCX+ oligo-like cells, without cytoplasmic processes, were scattered in white matter and cortex, visualized with all DCX antibodies; similar cells were often seen in a satellite position adjacent to neurons (Fig. 1i), particularly in deep cortical layers, as previously reported [40].

**DCX+ glial cell types**

Ramified DCX+ cells with multiple, branching processes were visualized mainly with the DCX antibody DCX Ab1 (Fig. 1e). Ramified DCX+ cells were present in all regions of all TLE cases, with and without HS, and all PM cases and noted in the gray and white matter. In the hippocampus, ramified DCX+ cells were particularly prominent in the hilus and subgranular zone of the dentate gyrus, extending through the granule cell layer. Occasional clusters or columns of DCX+ cells were seen (Fig. 1g) and proximity to CA1 pyramidal neurones. There were also present in the pes hippocampus and PHG in all cortical layers and white matter. Ramified cells were morphologically reminiscent of microglia and NG2+ cells as well as immature migrating neurons in the developing fetal brain in the periventricular zone (Fig. 1i). Occasional cells were also noted alongside vessels. In addition, a population of small round DCX+ oligo-like cells, without cytoplasmic processes, were scattered in white matter and cortex, visualized with all DCX antibodies; similar cells were often seen in a satellite position adjacent to neurons (Fig. 1i), particularly in deep cortical layers, as previously reported [40].

**DCX+ cells in amygdala**

**Surgical cases** The peri-amygdala cortex (PAC) and paralaminar/periventricular nuclei could be anatomically identified in surgical cases, but were incompletely represented. All DCX antibodies labelled clusters of small DCX+ cells, mainly in the superficial cortex of the PAC (Fig. 2b-d). These DCX+ cells were sometimes arranged in horizontal or vertical columns, with beaded linear processes (Fig. 2c). Fragments of amygdalar nuclei with a ventricular border (paralaminar nuclei) showed aggregates of small, intensely-labelled DCX+ cells and fibres intermingled with DCX-negative, mature neurons. Coarse fibre tracts and bundles of DCX+ processes were also occasionally noted in the amygdala of all surgical cases (Fig. 2d, inset). In addition, ramified DCX+ cells with cytoplasmic labelling, as observed in other regions, were widespread.

**PM cases:** Variable labelling of small DCX+ cell aggregates in the paralaminar nucleus of the amygdala was noted, particularly along the ventricle wall in the caudal amygdala (Fig. 2f, g). In these regions, clusters of small immature DCX+ nuclei were intermingled with larger and intermediate-sized DCX-negative neurones. (Fig. 2h). Some DCX+ cells were associated with fine beaded bipolar processes Fig. 2e). In the PAC, scattered small immature DCX+ cells with processes were noted, occasionally in clusters, mainly at the interface between layer I and II in either horizontal or perpendicular arrangements, as in the surgical cases.

**Double labelling studies and comparison of different DCX antibody labelling**

**DCX antibodies** DCX Ab1 showed the most extensive labelling of cells and processes in different regions but co-localization was confirmed in a proportion of small cells with the three other different DCX antibodies (Table 2, Fig. 3a). **Temporal neocortex:** In layer II of the temporal lobe, DCX+ tufted cells showed only rare co-localisation with mature neuronal marker NeuN (Fig. 3b, c). There was no cellular co-expression of DCX with mature glial marker GFAP immature stem cell markers nestin or GFAPδ, which both showed labelling of the sub-pial band of astrocytes (Fig. 3e). There were a few DCX+/Sox2+ cells noted. There were no CD34+ neuroglial cells in any of the surgical epilepsy cases. A minor proportion of small oligo-like DCX+ cells in the white matter co-expressed OLG2 (Fig. 3d); in contrast, MCM2/DCX+ cells were not observed (Fig. 3d inset). There was extensive co-localization between ramified DCX+ cells and Iba1, CD68 and, to a lesser extent, PDGFRβ. **Hippocampus body and pes:** Very rare DCX+/NeuN+ cells were observed in the granule cell layer (Fig. 3f). We did not observe any co-expression between GFAP, GFAPδ and nestin with DCX and these markers highlighted distinct cell populations in all regions (Fig. 3g). There was, however, prominent co-localization of ramified, multipolar DCX+ cells with Iba1 (Fig. 3h) and CD68 (Fig. 3i), particularly in the granule cell layer region. In addition, co-expression of DCX with PDGFRβ was evident in some small branching cells as well as MCM2 (Fig. 3j). Occasional double-labelling of small oligo-like cells with DCX and OLG2 as well as SOX2 was noted in hippocampal regions but not with CD34. **Amygdala:** Although DCX+ and nestin-expressing cells were observed in similar anatomical regions, particularly in the paralaminar nucleus, they highlighted distinct cell populations and processes (Fig. 3k, l). Multipolar, ramified DCX+ cells showed co-expression with Iba1 (Fig. 3m) and occasionally with PDGFRβ (Fig. 3n), but only in a proportion of cells. Cellular co-expression of DCX with NeuN, CD34, GFAP or MCM2 (Fig. 3o) was not observed in the amygdala of the cases examined and there was rare co-expression of DCX with OLG2 or SOX2.
Quantitative analysis
Based on the above findings our hypothesis was that quantitative analysis would confirm greater densities in the number of DCX+ cells in epilepsy than control groups. In the temporal lobe we confirmed higher linear densities for all morphological DCX+ cell types in surgical epilepsy cases compared to PM epilepsy cases and non-epilepsy controls (Fig. 1k) with statistically significant differences noted for ramified DCX+ cell populations ($p < 0.0001$). We also investigated their relationship with patient age and cortical region. The linear density of layer II cells compared to other DCX+ cell types showed an inverse correlation with age for all cases (surgical and PM) ($p = 0.001$) (Fig. 1l) as well as for surgical cases alone ($p = 0.016$) and for age of seizure onset ($p = 0.035$). There were significantly higher linear densities of tufted DCX+ cells in the FG compared to the ITG ($p = 0.004$) but not for other DCX+ cells types. We also hypothesized if there was a relationship between DCX+ linear densities and the presence of HS but did not confirm this. Similarly, we considered if DCX cell densities related to clinical parameters; there was no significant difference in DCX+ cells in relation to seizure types (focal or generalized seizures), history of aura (Fig. 1m) or if patients were seizure free (or not) two years...
following surgery. We noted an association for increased ramified DCX+ in cortical layer II in patients with severe verbal pre-operative memory deficit (Additional file 3: Figure S1; $p = 0.027$). In other regions (hippocampus, pes hippocampus, PHG and temporal pole and amygdala), semi-quantitative analysis of DCX+ ramified and small cell types in surgical cases did not show any significant differences between cases with HS or without HS, relationship to age at surgery, age of seizure onset, seizure types or outcome at 2 years. In PM cases, there were no significant differences in DCX populations in amygdala and PAC between epilepsy controls and controls; there was a negative correlation between DCX+ cells in the PAC and age over all PM cases ($p = 0.04$).

mRNA expression
From published data [21] DCX mRNA was expressed in all brain regions tested and exhibited temporal and regional significant differential expression (False Discovery Rate 5%). There was higher DCX mRNA expression in temporal, frontal and occipital regions and lower in cerebellum. DCX expression in the temporal cortex was higher in periods before and early birth (embryonic, fetal and early infancy) than in periods following the early infancy (late infancy, childhood, adolescence and adulthood) (Fig. 4b). We did not find significant differences in DCX expression in the temporal cortex between left and right hemispheres in controls [21] or TLE patients (adolescence and young and middle adulthood periods) (Fig. 4b). We did not find significant differences between patients with and without temporal lobe sclerosis and neither between patients with epilepsy and the 2 PM control groups (Fig. 4c) (For all $p$ values > 0.05 and fold change < 1.2).

Discussion
DCX is currently widely used as developmental marker for post-mitotic, immature neurons in the brain and for persistent neurogenesis in adulthood [14, 37]. Our study highlights the varied morphologies of DCX+ cells in adult TLE with ongoing expression supported by a parallel gene expression study. Tangled DCX+ cells in layer II of the temporal cortex did not express nestin, NeuN or MCM2, declined in numbers with age and did not significantly associate with clinical seizure semiology, memory dysfunction or the presence of HS. Amygdala DCX+ immature neuronal populations were primarily located in the paralaminar nucleus, but their number and morphology were not different between cases and controls. We also identified a subset of ramified and small cells with DCX antibodies, representing a range of glial cell types and supporting non-neuronal DCX expression; these were increased in number in the neocortex in epilepsy, associated with memory impairment and may represent reactive populations.

**Temporal cortical DCX+ cells in epilepsy**
The presence of persistent, immature, DCX+ neocortical cells in layer II, primarily in the temporal lobe and piriform cortex, has been recognized in a range of adult mammalian species since 2001 (reviewed in [6]). They are less studied in humans and their precise physiological function remains elusive. They have been variable termed ‘tangled and tufted’ cells or ‘semilunar/transitional’ neurons, co-express PSA-NCAM or other immature neuronal markers but reported to be mainly negative with mature neuronal marker NeuN. Although the number of DCX+ cortical cells decline with age, they are considered to endow the cortex with enhanced synaptic plasticity [23] and roles in olfactory learning and memory have been postulated [6]. In mammals they are not considered to be newly generated in adulthood, but to arise during development from migrating cells of the lateral cortical stream [2]. A persistent temporal lobe migratory stream has also been recently described in adult mammals, extending from the temporal pole of the lateral ventricle to the piriform cortex and amygdala [14] and we have also recently reported evidence for vestiges of a similar migratory stream in the human adult mesial temporal lobe [27]. In TLE an increased plexus of PSA-NCAM-positive neurons was reported in layer II of the entorhinal cortex [30] and increased DCX+ cells were noted in the temporal neocortex in epilepsy compared to controls with evidence for some maturation with NeuN expression, yet maintaining a persistent immature phenotype (98% co-expressing PSA-NCAM and 82% Tuj1) [28]. Similar tangled DCX+ cells in layer II were also prominent in young patients with FCD type Ia [40].

In the current series, layer II DCX+ temporal neocortical cells showed infrequent NeuN expression, in keeping with some previous studies [15, 40]; the additional lack of expression of the stem cell marker nestin could support their intermediate differentiation between progenitor cells and mature neurons [27]. We confirmed their anatomical distribution, with increased density in more mesial temporal neocortex, as suggested in previous reports [6, 28]. They were not prominent in the parahippocampal gyrus cortex however and we also observed a significant decline in the number of tangled cells with age. In our recent study of TLE/HS patients aged over 50 years with early Alzheimer-like pathology in temporal lobe resections, we reported a lack of tau accumulation in layer II DCX+ cells, suggesting their resistance to age-related neurodegeneration [42], as also supported by experimental models [52]. We have shown in this study that the number of tangled neurons is not increased in epilepsy patients compared to controls, nor is the number related to clinical olfactory/ sensory auras, memory dysfunction the presence of hippocampal sclerosis or post-surgical outcome. In a parallel gene expression study from patients with TLE/HS there
were no significant differences in patients with additional temporal lobe superficial cortical neuronal loss and gliosis (also called temporal lobe sclerosis) \[43\] from those with normal/preserved neocortex. These findings could suggest that layer II DCX+ cell types are unlikely to be clinical or pathologically relevant to functional and acquired pathologies in temporal lobe epilepsy.

**Amygdala and DCX+ populations**

The amygdala can initiate seizures in TLE and volume changes, including enlargement are recognized in TLE in addition to gliosis [3]. During development, migrating DCX+ cells in the lateral cortical stream give rise to neuronal and glial populations in the amygdala [2]; persisting DCX+ cells in adulthood have been reported in the primate amygdala and PAC, forming chains of cells, a proportion of which co-express NeuN, their number declining with age [52]. Similar cell types were also confirmed in the human amygdala [29], in particular the paralaminar nucleus of the amygdala, where abundant rests of immature DCX+ neurons were shown in one study [10]. The paralaminar nucleus, which sits along the ventricle wall, is composed of nodules of small primitive appearing cells, and is interconnected with other amygdala nuclei receiving high serotonergic input. Its precise functions are uncertain [10]. In the current study, DCX+ immature cells, primarily in the paralaminar nucleus and PAC, were confirmed to exist in the amygdala, in both surgical tissue as well as PM cases. Diminished populations were associated with increasing age but the cells did not show atypical morphology or altered numbers in epilepsy or associate with the presence

**Fig. 4 DCX mRNA expression data.**

**a** Significant DCX temporally differential expression between periods on temporal cortex (p value: $4.5 \times 10^{-13}$) [21]. Periods 1: Embryonic, 2: Early Fetal, 3: Early midfetal 4: Late midfetal 5: Late fetal 6: Neonatal and early infancy 7: Late infancy 8: Early childhood 9: Middle and Late adulthood 10: Adolescence 11: Young adulthood 12: Middle adulthood 13: Late adulthood **b** DCX expression on right (R) and left (L) temporal cortex on patients with temporal lobe epilepsy (TLE) [22] and controls [21] after correcting for batch differences. Periods 10, 11 and 12 **c** DCX mRNA expression data from 83 TLE (divided into cases with or without temporal lobe sclerosis (TS) (neuronal loss from the superficial neocortex in addition to hippocampal sclerosis [43]) and controls from the MRC brain bank, Edinburgh, after correcting for batch, age, gender and RIN differences. Periods 10 to 13
of hippocampal sclerosis. Nevertheless, application of DCX+ may be helpful in clinical practice to enable their anatomical identification and avoid over-interpretation as small malformations or hamartias, described in surgical resections in TLE [17].

DCX – A reliable marker of neurogenesis in the mature human brain?
There is increasing awareness of DCX expression in non-neuronal cells types. DCX-expressing astroglial cells have been noted in adult post mortem tissues in patients with epilepsy and controls [46], in balloon cells in FCD IIB and multipolar astroglial like cells in temporal lobe sclerosis [40]. DCX+ stellate cells have been reported in the vicinity of acute infarcts with co-expression of astroglial lineage markers (GFAP, S100) rather than microglial or mature neuronal markers as NeuN [25]. In another study however, DCX+ ‘rod’ cells in the infant hippocampal subgranular zone region, that morphologically resembled microglia, lacked CD68 and HLADR expression and were argued to represent neural progenitor cell types [34]. In adult mammals, DCX+ cells are reported to be enriched in the subgranular zone of the hippocampus, and are described as ‘ramified’, although exhibiting more overt neuronal morphology with apical dendrites [14, 36]. Experimental tracing studies of DCX+ cell fate during temporal lobe development show that 95% give rise to TBR1-positive pyramidal neurons but a small proportion differentiate to GFAP astrocytes (3.4%) and a further population of small bipolar cells with sparsely branching processes are of uncertain lineage (1.7%) [2]. Single cell transcriptomics of isolated DCX+ populations has also provided evidence of cell subsets enriched for divergent pathways, including astrocytic and myelinating oligodendrogial fates [15]. Identification of DCX expression in oligodendrogial precursor cells (OPC) was proposed to reflect cell migration rather than neuronal differentiation [7] and DCX expression is also speculated to have a role in glioblastoma infiltration [1].

Our current study adds further support to DCX expression in non-neuronal cell types. We noted frequent ramified, multipolar DCX+ cells and oligo-like cells without processes in many regions, including the SGZ, and these were significantly increased in surgical TLE compared to controls. These were observed mainly with one DCX antibody although overlap of expression was noted in a proportion of small cells with other commercial DCX antibodies, suggesting different sensitivities. Although DCX+ ramified cells in the dentate gyrus resembled cells in the developing human sub-ventricular zone, they lacked the typical unipolar or bipolar morphology [36]. Furthermore, we confirmed that a proportion of ramified DCX+ cells co-expressed microglial markers, as well as PDGFRβ, supporting non-neuronal lineages. Significantly more ramified DCX+ cells were noted in surgical epilepsy cases in the temporal cortex compared to controls. However there were no differences between epilepsy cases with or without hippocampal sclerosis. These different observations suggest enhanced DCX expression in reactive glial cells types in epilepsy could be independent of underlying pathology.

The observation of DCX in microglia was an unexpected finding. Microglial cells are dynamic, motile cells which show changes in morphology in response to brain activity and injury, with increasingly recognized diverse and complex roles [8, 32] including neurodevelopment as well as epilepsy [13]. Understanding of these cells has advanced with proteomic and transcriptomic analysis of isolated microglia, aiming to identify specific proteins more abundantly expressed, as candidate lineage and activation markers [12, 38, 48, 53] (see https://omictools.com/glia-open-access-database-tool). Although proteomics and gene expression studies have suggested that DCX is not expressed in microglia at significant levels [18–20, 38, 50, 53], differential gene expression studies do show DCX is dependent on their activation state. For example, one study using laser single cell capture and gene expression of microglial cell types of different morphology showed that DCX was highly enriched in activated amoeboid microglia and confirmed by immunohistochemistry and PCR of a murine microglial cell line [35]. Recent studies have also highlighted expression of putative immature neuronal markers in reactive cell types, including microglia in human slice cultures [47].

Intriguingly we also noted PDGFRβ+ co-expression in some of the ramified DCX+ cells in TLE tissues; DCX expression has been previously shown in pericytes [53]. Although PDGFRβ+ is widely recognized as a CNS pericyte marker [41] it is also expressed in OPC/NG2 perivascular glial cell types, which are reactive to seizures [16, 26, 31, 39]. We also noted occasional DCX+ small cells to co-express Olig2 in keeping with reported low DCX expression in OPC lineages [7, 53]. In our parallel gene expression study from TLE cortex, DCX expression was confirmed in adult temporal cortex and, although expression was not significantly increased in TLE compared to controls, more detailed single cell analysis is warranted to further investigate differential cellular expression in epilepsy. Our findings therefore support ongoing DCX expression in adults; expression in non-neuronal cells, particularly in adults undergoing surgery for refractory epilepsy, may suggest aberrant upregulation under pathological conditions, including seizures.

Study limitations
There are several limitations to the study. The ages in the epilepsy and control groups for the histology were not precisely matched as in the mRNA study and although ramified DCX+ cell densities did not show a relationship
with age, we cannot exclude that this may have had an effect. The PM cases with epilepsy and HS did not all have syndromic TLE and limited memory tests were available. The gene expression data on MTG was obtained on homogenized cortex from all cases rather than micro-dissected cortical layers or cells and was not carried out on the ITG or FG where greater numbers of DCX+ cells are observed. We did not have complete representation of the FG in the surgical specimens, compared to the PM cases in the analysis of Layer II DCX+ cells and in the amygdala surgical specimens were fragmentation which limits analysis of the entire nucleus.

Conclusions
DCX identifies a range of morphological cell types in temporal lobe epilepsy, including immature populations in the superficial cortex and amygdala that decline with age but may not be specifically relevant to the epilepsy or local pathology. We observed DCX+ reactive glial cell types, including microglial lineages with some evidence for increased numbers in epilepsy tissue. This suggests that DCX not only is expressed in residual immature neuronal cell types, but may have a role in brain responses to seizure injury.

Additional files

Additional file 1: Table S1. Detail of each case used in the study including clinical and psychometric data and the type of study carried out (DOCX 29 kb)

Additional file 2: Supplementary Methods (DOCX 18 kb)

Additional file 3: Figure S1. Bar graphs of the relationship between pre-operative memory function and DCX+ cells in the superficial temporal lobe. A. There was an association between severe memory deficit and increased ramified type DCX+ cells (p = 0.027). However the number of patients in this series is small and requires validation with a larger cohort. B. There was no association between the number of tufted DCX+ neuronal cells in layer II of the temporal cortex and pre-operative memory function. (JPG 181 kb)

Additional file 4: Figure S2. Split channels for DCX double labelling as indicated in temporal lobe, hippocampus and amygdala for images shown in Fig. 3. (TIF 15727 kb)

Abbreviations
DCX: Doublecortin; FG: Fusiform gyrus; HS: Hippocampal sclerosis; ILAE: International league against epilepsy; ITG: Inferior temporal gyrus; MTG: Middle temporal gyrus; OPC: Oligodendroglial precursor cells; PAC: Periamygdala cortex; PHG: Parahippocampal gyrus; PM: Post mortem; TLE: Temporal lobe epilepsy

Acknowledgements
We are grateful to the MRC sudden death brain bank in Edinburgh for the provision of control cases, to the Human Developmental Biology Research for paediatric and fetal brain specimens and to Simon Paine and Tom Jacques for the provision of cases from Great Ormond Street Hospital.

Funding
This work is supported by a grant from the MRC MR/J01270X/1. MM is supported by Marie Curie International Re-integration Grant (FP7-PEOPLE-2009-RG grant No 256545) and Epilepsy Research UK (F1208). JL is currently supported by EPITARGET. This work was undertaken at UCLH/UCL, which received a proportion of funding from the Department of Health’s NIHR Biomedical Research Centres funding scheme. The UCL Epilepsy Brain and Tissue Bank is supported by the Katy Baggott Foundation through the Epilepsy Society.

Availability of data and materials
The sequencing datasets generated and or analysed during the current study are not publicly available at the present time as they are part of an ongoing study and publication in preparation but will then become available on reasonable request.

Authors’ contributions
JL and MT prepared the manuscript and figures and carried out all the data analysis. JL carried out the double labelling studies. CR carried out the single labelling studies. MM carried out all the gene expression data and analysis. AM, AM, SS and PT provided all the clinical data. All authors have been involved in final manuscript approval.

Ethics approval and consent to participate
The study has ethical approval and all cases were consented for use in research (Ethics committee approval National research ethics committee: NRES17/SC/0573).

Competing interests
All co-authors have no personal, professional or financial relationships that could potentially be construed as a conflict of interest.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, Queen Square, London WC1N 1BG, UK. 2Department of Neuropathology, National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK. 3Department of Neurology, National Hospital for Neurology and Neurosurgery, London, UK. 4Department of Neurophysiology, National Hospital for Neurology and Neurosurgery, London, UK. 5Department of Neurosurgery, National Hospital for Neurology and Neurosurgery, London, UK. 6Chalfont Centre for Epilepsy, Chesham Lane, Chalfont St Peter, Buckinghamshire SL9 0RJ, UK. 7Department of Biomedical Sciences, University of Westminster, W1W6UJ, London, UK.

Received: 21 May 2018 Accepted: 3 July 2018 Published online: 13 July 2018

References
1. Ayanlaja AA, Xiong Y, Gao Y, Ji G, Tang C, Abdikani Abdullah Z, Gao D (2017) Distinct features of Doublecortin as a marker of neuronal migration and its implications in Cancer cell mobility. Front Mol Neurosci 10:199. https://doi.org/10.3389/fnmol.2017.00199
2. Bai J, Ramos RL, Paramasivam M, Siddiqi F, Ackman JB, LoTurco JJ (2008) The role of DCX and LIS1 in migration through the lateral cortical stream of developing forebrain. Dev Neurosci 30:144–156. https://doi.org/10.1159/000109859
3. Beh SMJ, Cook MJ, D’Souza WJ (2016) Isolated amygdala enlargement in temporal lobe epilepsy: a systematic review. Epilepsy & behavior: E&B 60:33–41. https://doi.org/10.1016/j.yebeh.2016.04.015
4. Blumcke I, Spinafello R, Haaker G, Cosas R, Kobow K, Bien CG, Pfafflin M, Elger C, Widman G, Schramm J et al (2017) Histopathological findings in brain tissue obtained during epilepsy surgery. N Engl. J. Med. 377:1648–1656. https://doi.org/10.1056/NEJMoa1703784
5. Blumcke I, Thom M, Aronica E, Armstrong DD, Bartolomei F, Bemasconi A, Bemasconi N, Bien CG, Cendes F, Coras R et al (2013) International consensus classification of hippocampal sclerosis in temporal lobe epilepsy: a Task Force report from the ILAE Commission on Diagnostic Methods. Epilepsia 54:1315–1329. https://doi.org/10.1111/epi.12200
6. Bonfanti L, Nacher J (2012) New scenarios for neuronal structural plasticity in non-neurogenic brain parenchyma: the case of cortical layer II immature neurons. Prog Neurobiol 98:1–15. https://doi.org/10.1016/j.pneurobio.2012.05.002
45. Verwer RW, Sluiter AA, Balesar RA, Baaijen JC, de Witt Hamer PC, Speijer D, Li Y, Swaab DF (2015) Injury response of resected human brain tissue in vitro. Brain Pathol 25:454–468. https://doi.org/10.1111/bpa.12189
46. Verwer RW, Sluiter AA, Balesar RA, Baayen JC, Noske DP, Driven CM, Wouda J, van Dam AM, Lucassen PJ, Swaab DF (2007) Mature astrocytes in the adult human neocortex express the early neuronal marker doublecortin. Brain J Neurol 130:321–3335. https://doi.org/10.1093/brain/asm264
47. Verwer RW, Sluiter AA, Balesar RA, Baayen JC, Speijer D, Idema S, Swaab DF (2016) Altered loyalties of neuronal markers in cultured slices of resected human brain tissue. Brain Pathol 26:523–532. https://doi.org/10.1111/bpa.12330
48. Wes PD, Holtman IR, Boddeke EW, Moller T, Eggen BJ (2016) Next generation transcriptomics and genomics elucidate biological complexity of microglia in health and disease. Glia 64:197–213. https://doi.org/10.1002/glia.22866
49. Xiong K, Luo DiW, Patrylo PR, Luo XG, Struble RG, Clough RW, Yan XX (2008) Doublecortin-expressing cells are present in layer II across the adult Guinea pig cerebral cortex: partial colocalization with mature interneuron markers. Exp Neurol 211:271–282. https://doi.org/10.1016/j.expneurol.2008.02.003
50. Yoo Y, Byun K, Kang T, Bayarsaikhan D, Kim JY, Oh S, Kim YH, Kim SY, Chung WI, Kim SJ et al (2019) Amyloid-beta-activated human microglial cells through ER-resident proteins. J Proteome Res 14:214–223. https://doi.org/10.1021/pr500926r
51. Zhang L, Hernandez VS, Estrada FS, Lujan R (2014) Hippocampal CA field neurogenesis after pilocarpine insult: the hippocampal fissure as a neurogenic niche. J Chem Neuroanat 56:45–57. https://doi.org/10.1016/j.jchemneu.2014.02.002
52. Zhang XM, Cai Y, Chu Y, Chen EY, Feng JC, Luo XG, Xiong K, Struble RG, Clough RW, Patrylo PR et al (2009) Doublecortin-expressing cells persist in the associative Cereb Cortex and amygdala in aged nonhuman Primates. Front Neuroanat 3:17. https://doi.org/10.3389/neuro.05.017.2009
53. Zhang Y, Chen K, Sloan SA, Bennett ML, Schoze AR, O’Keeffe S, Phatnani HP, Guarnieri P, Caneda C, al RN (2014) An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the Cereb Cortex. J Neurosci Off J Soc Neurosci 34:11929–11947. https://doi.org/10.1523/JNEUROSCI.1860-14.2014